Research programme: PEGylated protein therapeutics - MacroGenics/PolyTherics
Latest Information Update: 16 Jul 2016
At a glance
- Originator MacroGenics; PolyTherics
- Class Bispecific antibodies; Recombinant proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom (Parenteral)
- 06 Dec 2010 Early research in Undefined indication in United Kingdom (Parenteral)